GlassScriptPhysician profile
Anthony Taylor White
NPI 1548239585
$7,719.33
in general payments reported to CMS, 2019-2025
39 companies · $36.39 in 2025
The $36.39 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,040 · 2020: $779 · 2021: $1,368 · 2022: $1,705 · 2023: $1,761 · 2024: $1,030 · 2025: $36.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,827.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $886.46 | 2019-2024 | |
| Pfizer INC. | $832.81 | 2019-2024 | |
| Medtronic, INC. | $789.02 | 2021-2024 | Onyx Frontier, Symplicity G3, Micra |
| Abbott Laboratories | $781.39 | 2019-2023 | Pressurewire, Assurity, Mitraclip |
| Amgen INC. | $638.62 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $474.55 | 2019-2024 | Jardiance |
| Medtronic Vascular, INC. | $398.49 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $381.67 | 2020-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $358.68 | 2021-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $244.49 | 2019-2024 | Farxiga, Wainua |
| Sanofi-Aventis U.S. LLC | $230.31 | 2019-2023 | |
| Novo Nordisk INC | $191.26 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Endologix LLC | $186.14 | 2020-2021 | |
| Edwards Lifesciences Corporation | $171.92 | 2023-2024 | Sapien 3 Ultra Resilia |
| W. L. Gore & Associates, INC. | $163.19 | 2019 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.